Lawsuits and product recalls undermine J&J 2Q results
This article was originally published in Scrip
Lawsuits and product recalls had a negative but not unexpected impact on Johnson & Johnson's second quarter profits, although currency exchange rates and pharmaceuticals provided a welcome boost to revenues. Net income declined by 20% to $2.8 billion ($1 a share) from $3.4 billion ($1.23 a share) in 2Q 2010. Johnson & Johnson was hit by expenses associated with litigation, the recall of brands such as Tylenol and Motrin, and restructuring issues.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.